4 results about "Increased platelets" patented technology

Among the various aspects of the present disclosure is the provision of compositions and methods for platelet storage supplementation with an amino acid, such as taurine.

The invention relates to the technical field of medicines, in particular to application of unsaturated hyaluronic acid tetrasaccharide to preparation of a product for increasing the number of platelets or the hematocele of the platelets. Animal experiments show that the unsaturated hyaluronan tetrasaccharide can significantly increase the number of platelets in mouse blood and platelet hematocrit for the first time. In addition, the platelet distribution width and the large platelet ratio can be reduced. A further research shows that the unsaturated hyaluronic acid tetrasaccharide has good tolerance and has high selectivity on the action of platelets in blood. The unsaturated hyaluronic acid tetrasaccharide disclosed by the invention has an important application prospect in preparation of a product for increasing the number of platelets or the hematocele of the platelets.

Methods of accelerating clot formation and increasing clot deposition in a hemophiliac subject. A vagal nerve stimulator (VNS) may be implanted in a hemophiliac subject. The hemophiliac subject may have developed antibodies to factor VIII and not been administered a clotting factor within the last 48 hours. The vagus nerve of the subject may be stimulated in a manner that increases platelet intracellular calcium and / or activates splenic acetylcholine-synthesizing T lymphocytes using the implanted VNS.

The application discloses an anti-platelet GPIb-IX antibody and application thereof, and belongs to the technical field of biological medicines. The application selects the starting signal protein GPIb-IX of arterial thrombosis as a target, and prepares an anti-human GPIb-IX humanized antibody. Specifically, human platelets are used as antigens to immunize mice, and a mouse-derived anti-human GPIb-IX antibody is obtained through screening and preparation, a humanized anti-GPIb-IX antibody ATHA is constructed by mutating a human-derived sequence, the heavy chain variable region of the ATHA comprises a VH-CDR3 shown in SEQ ID NO. 1, and the light chain variable region comprises a VL-CDR3 shown in SEQ ID NO. 2. The Fab segment of the ATHA can effectively inhibit platelet activation mediated by the GPIb-IX receptor, inhibit thrombosis in the body without accompanying side effects such as platelet reduction and bleeding, and has the characteristics of high specificity, good safety and small side effects. Meanwhile, the ATHA can remove platelets. Therefore, the ATHA-Fab has clinical value as a new anti-thrombotic drug, and can be used for treating diseases related to arterial thrombosis. The ATHA can remove platelets, and can be used for treating diseases with increased platelet quantity or removing platelets in the body.